U.S. Markets open in 1 hr 16 mins
  • S&P Futures

    4,396.25
    +1.75 (+0.04%)
     
  • Dow Futures

    34,938.00
    -15.00 (-0.04%)
     
  • Nasdaq Futures

    14,993.75
    +46.00 (+0.31%)
     
  • Russell 2000 Futures

    2,201.40
    +14.70 (+0.67%)
     
  • Crude Oil

    71.98
    +0.33 (+0.46%)
     
  • Gold

    1,795.40
    -4.40 (-0.24%)
     
  • Silver

    24.77
    +0.12 (+0.49%)
     
  • EUR/USD

    1.1811
    -0.0015 (-0.1299%)
     
  • 10-Yr Bond

    1.2340
    0.0000 (0.00%)
     
  • Vix

    18.91
    +1.33 (+7.57%)
     
  • GBP/USD

    1.3874
    -0.0005 (-0.0361%)
     
  • USD/JPY

    110.0590
    +0.2920 (+0.2660%)
     
  • BTC-USD

    40,616.97
    +2,688.88 (+7.09%)
     
  • CMC Crypto 200

    947.96
    +71.73 (+8.19%)
     
  • FTSE 100

    7,007.69
    +11.61 (+0.17%)
     
  • Nikkei 225

    27,581.66
    -388.56 (-1.39%)
     

Would Shareholders Who Purchased Atara Biotherapeutics' (NASDAQ:ATRA) Stock Three Years Be Happy With The Share price Today?

·2 min read

As every investor would know, not every swing hits the sweet spot. But really bad investments should be rare. So consider, for a moment, the misfortune of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) investors who have held the stock for three years as it declined a whopping 72%. That would certainly shake our confidence in the decision to own the stock. The falls have accelerated recently, with the share price down 21% in the last three months. This could be related to the recent financial results - you can catch up on the most recent data by reading our company report.

See our latest analysis for Atara Biotherapeutics

Given that Atara Biotherapeutics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

Atara Biotherapeutics shareholders are down 1.6% for the year, but the market itself is up 46%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, longer term shareholders are suffering worse, given the loss of 4% doled out over the last five years. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Atara Biotherapeutics is showing 4 warning signs in our investment analysis , you should know about...

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.